Phibro Animal Health Corporation (PAHC) SEC Filings & Earnings Calls

Regulatory risk: virginiamycin in Brazil; minimal sales assumed in FY27 guidance, potential upside if approved.

“we have assumed only minimal virginiamycin sales in Brazil in our outlook. As a result, a favorable regulatory outcome would represent a modest potential upside” · word for word

Manufacturing closure: Chicago Heights facility closure may incur one-time costs and operational disruption.

“decided to close our Chicago Heights manufacturing facility as part of a strategic consolidation of our manufacturing network. Approximately 100 employees will be affected”

Brazil virginiamycin ban

“On April 27, 2026, MAPA published an ordinance prohibiting the importation, manufacture and marketing of antimicrobial feed additives classified as important in human or veterinary medicine, including virginiamycin and bacitracin, for performance enhancement.” · word for word

FDA carbadox withdrawal

“In November 2023, the FDA issued a final order to revoke the approved method for detecting carbadox residues.” · word for word

EU re-registration uncertainty

“There can be no guarantee that these submissions will be reviewed favorably or in a timely manner.” · word for word

Antimicrobial resistance regulation

“The issue of the potential for increased bacterial resistance to certain antibiotics used in certain food-producing animals is the subject of discussions on a worldwide basis” · word for word

CEO transition may introduce strategic uncertainty.

“Appointment of new CEO with performance-based RSUs tied to stock price targets.”

Insider selling pressure

“BFI entered into a Rule 10b5-1 sales plan to sell up to 750,000 shares of Class A Common Stock through March 17, 2027” · word for word

Insider selling pressure

“BFI entered into a Rule 10b5-1 sales plan to sell up to 750,000 shares of Class A Common Stock through March 17, 2027” · word for word

Regulatory development in Brazil affecting certain antimicrobial products; potential impact on Animal Health segment.

“After quarter end, we announced a regulatory development in Brazil affecting certain antimicrobial products.” · word for word

FDA Carbadox Withdrawal Risk

“Sales of Mecadox (carbadox) for the twelve months ended March 31, 2026 were approximately $22 million. Should we be unable to successfully defend the safety of the product, the loss of carbadox sales will have an adverse effect on our financial condition and results of operations.” · word for word

Brazil Antimicrobial Ban

“On April 27, 2026, MAPA published its Ordinance prohibiting the importation, manufacture, marketing and use of performance enhancing feed additives containing antimicrobials classified as important in human or veterinary medicine, including virginiamycin and bacitracin.” · word for word

Middle East Conflict Operational Disruption

“Our Israeli manufacturing facilities and local operations account for 17% of our consolidated assets as of March 31, 2026, and 16% of our consolidated net sales for the nine months ended March 31, 2026.” · word for word

Tariff Recovery Uncertainty

“The ruling did not address potential refunds, and therefore the ultimate availability, timing, and amount of the recovery of any potential refunds of these tariffs is highly uncertain and may be subject to further legal, regulatory, and administrative developments.” · word for word

Increased debt capacity may lead to higher leverage if utilized.

“Amendment No. 1 increased revolving credit commitment by $125M.”

Regulatory ban in Brazil on key antimicrobial products could reduce revenue from growth promoter segment; mitigated by transition period and therapeutic registrations.

“Prohibition of virginiamycin and bacitracin as growth promoters; company expects limited impact on FY2026 results.”

Insider Control Risk

“BFI directly owns 95,880 shares of Class A Common Stock and 19,496,034 shares of Class B Common Stock as of April 23, 2026, representing 48.3% of the total number of shares of Class A Common Stock outstanding, assuming that all outstanding shares of Class B Common Stock are converted into shares of Class A Common Stock.” · word for word

Insider Control Risk

“BFI directly owns 95,880 shares of Class A Common Stock and 19,496,034 shares of Class B Common Stock as of April 23, 2026, representing 48.3% of the total number of shares of Class A Common Stock outstanding, assuming that all outstanding shares of Class B Common Stock are converted into shares of Class A Common Stock.” · word for word

Geopolitical conflict in Israel

“Our Israeli manufacturing facilities and local operations account for 16% of our consolidated assets as of December 31, 2025, and 16% of our consolidated net sales for the six months ended December 31, 2025.” · word for word

FDA carbadox withdrawal

“Should we be unable to successfully defend the safety of the product, the loss of carbadox sales will have an adverse effect on our financial condition and results of operations.” · word for word

Tariff exposure

“These measures could introduce supply chain inefficiencies, challenge current trade agreements with certain nations, and affect the cost and availability of materials critical to our products.” · word for word

High leverage from acquisition

“Interest expense, net of $11.8 million for the three months ended December 31, 2025 increased $2.8 million, as compared to the three months ended December 31, 2024, due to higher average debt levels associated with the financing of the Acquisition.” · word for word

Foreign currency losses impacting results.

“Foreign currency losses net $2.1M in Q2 2026.”

Higher input and distribution costs.

“Partially offset by higher input and distribution costs.” · word for word

Leadership transition risk; family succession may raise governance concerns.

“CEO resignation and appointment of son as successor.”

Mecadox Regulatory Risk

“Should we be unable to successfully defend the safety of the product, the loss of carbadox sales will have an adverse effect on our financial condition and results of operations. Sales of Mecadox (carbadox) for the twelve months ended September 30, 2025 were approximately $22 million.” · word for word

Geopolitical Risk - Israel

“Our Israeli manufacturing facilities and local operations account for 16% of our consolidated assets as of September 30, 2025, and 17% of our consolidated net sales, for the three months ended September 30, 2025.” · word for word

Foreign Exchange Risk

“Foreign currency losses, net for the three months ended September 30, 2025, were $2.9 million, as compared to $0.4 million of net losses for the three months ended September 30, 2024.” · word for word

High Debt Levels

“Interest expense, net of $12.1 million for the three months ended September 30, 2025 increased by $4.4 million, as compared to the three months ended September 30, 2024, due to higher debt levels associated with the financing of the Acquisition.” · word for word

Dependence on animal health segment for growth; concentration in MFA portfolio

“Animal Health segment drove 55% growth; MFA portfolio contributed $80.5M incremental revenue from acquisition”